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Background. Cannabis use is associated with an earlier age at onset of psychotic illness. The aim of the present study
was to examine whether this association is confounded by gender or other substance use in a large cohort of patients
with a non-aﬀective psychotic disorder.
Method. In 785 patients with a non-aﬀective psychotic disorder, regression analysis was used to investigate the
independent eﬀects of gender, cannabis use and other drug use on age at onset of ﬁrst psychosis.
Results. Age at onset was 1.8 years earlier in cannabis users compared to non-users, controlling for gender and other
possible confounders. Use of other drugs did not have an additional eﬀect on age at onset when cannabis use was
taken into account. In 63.5% of cannabis-using patients, age at most intense cannabis use preceded the age at onset of
ﬁrst psychosis. In males, the mean age at onset was 1.3 years lower than in females, controlling for cannabis use and
other confounders.
Conclusions. Cannabis use and gender are independently associated with an earlier onset of psychotic illness. Our
ﬁndings also suggest that cannabis use may precipitate psychosis. More research is needed to clarify the
neurobiological factors that make people vulnerable to this precipitating eﬀect of cannabis.
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Introduction
As early age at onset of psychotic illness is associated
with poor outcome (Lauronen et al. 2007) and with
more frequent hospitalizations over the course of ill-
ness (Rabinowitz et al. 2006), better insight into factors
that are associated with an early age of onset of psy-
chotic disorders is important.
One of the factors associated with an earlier age at
ﬁrst psychotic episode is cannabis use (Buhler et al.
2002 ; Veen et al. 2004 ; Barnes et al. 2006 ; Mauri et al.
2006 ; Addington & Addington, 2007 ; Gonza´lez-Pinto
et al. 2008 ; Ongur et al. 2009 ; Sugranyes et al. 2009 ;
Barrigon et al. 2010 ; Foti et al. 2010 ; Pelayo-Tera´n et al.
2010 ; De Hert et al. 2011 ; Large et al. 2011). In a recent
meta-analysis, the mean age at onset of psychosis
was 2.70 years lower in cannabis users compared to
non-users (Large et al. 2011). However, some studies
have not found diﬀerences in age at onset of psychosis
between cannabis users and non-users (Bersani et al.
2002 ; DeRosse et al. 2010 ; Goldberger et al. 2010).
A second factor associated with age at onset of
psychosis is gender : males are 3 to 4 years younger
at illness onset compared to females (Hambrecht et al.
1992 ; Szymanski et al. 1995 ; Castle et al. 1998 ; Leung &
Chue, 2000 ; Hafner, 2003). As cannabis use is more
prevalent among male patients with schizophrenia
(e.g. Hambrecht & Hafner, 1996 ; Gonza´lez-Pinto et al.
2008 ; Sevy et al. 2010), some studies have investigated
the relationship between cannabis use and age at
onset of ﬁrst psychosis after correction for gender.
These studies showed that cannabis use remained an
independent predictor of an earlier age at ﬁrst psy-
chotic episode after correction for gender (Veen et al.
2004 ; Barnes et al. 2006 ; Gonza´lez-Pinto et al. 2008 ;
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Ongur et al. 2009 ; Sugranyes et al. 2009 ; Barrigon et al.
2010 ; De Hert et al. 2011). In only one of these studies
(Barnes et al. 2006) did gender remain an independent
predictor for age at onset of psychosis after adjusting
for cannabis use. This suggests that the frequently
reported association between gender and age at onset
is spurious or might be the consequence of a lack of
power in the studies that did not ﬁnd this relationship
because most of these studies included a relatively
small number of female patients (range of number of
included females was 36–99). However, lack of power
was not an issue in the one study that did include a
relatively large number (n=236) of females (De Hert
et al. 2011).
A third factor that could confound the association
between cannabis use and age at onset of psychosis
is the use of other illicit drugs, such as stimulants
(Brady et al. 1991 ; Satel et al. 1991 ; Landabaso et al.
2002 ; McKetin et al. 2006) and hallucinogens (Vardy &
Kay, 1983), that have been reported to precipitate
psychotic symptoms. Although these drugs have
not yet been shown to have an additional aﬀect on
age at onset of psychosis (Barnes et al. 2006 ; Gonza´lez-
Pinto et al. 2008 ; Barrigon et al. 2010), the non-
signiﬁcant relationship between these other illicit
drugs and age of onset might also be the result of in-
suﬃcient power.
In the current study we assessed the independent
eﬀects of gender, cannabis use and additional drug
use on age at onset of ﬁrst psychosis in a large sample
of patients receiving treatment for non-aﬀective psy-
chotic illness, including a relatively large sample of
females, and users of drugs other than cannabis.
Method
Participants
The patients took part in the Genetic Risk and
Outcome of Psychosis (GROUP) study, a multisite
longitudinal cohort study in The Netherlands
and Belgium that focuses on vulnerability and resili-
ence factors for variation in expression and course
of treatment-seeking patients with non-aﬀective psy-
chotic disorders (Korver et al., in press). Inclusion
criteria for patients were : (1) age between 16 and
50 years, (2) a diagnosis of non-aﬀective psychotic
disorder [schizophrenia, schizophreniform disorder,
schizo-aﬀective disorder, delusional disorder, brief
psychotic disorder, psychotic disorder not otherwise
speciﬁed (NOS)] according to DSM-IV (APA, 1994),
(3) onset of contact with psychiatric caregivers for
psychosis less than 10 years before study entrance, and
(4) good command of the Dutch language. In selected
representative geographical areas in The Netherlands,
patients were identiﬁed by clinicians working in re-
gional or academic psychosis centres whose caseloads
were screened for inclusion criteria (prevalence
sample). In addition, all consecutive patients present-
ing at these services, as either out- or in-patients, were
recruited for the study (incidence sample). All partici-
pants gave written informed consent after complete
description of the study. The study was approved by
the human subject review boards of all four academic
centres.
Measures
Clinical measures
To establish a DSM-IV (APA, 1994) diagnosis of psy-
chotic disorder, two diﬀerent structured diagnostic
instruments were used in the four GROUP study
sites : three sites used the Comprehensive Assessment
of Symptoms and History (CASH; Andreasen et al.
1992 ; Divisie Psychiatrie Academisch Ziekenhuis
Utrecht, 2003) and one site used the Schedules for
Clinical Assessment in Neuropsychiatry (SCAN 2.1 ;
Wing et al. 1990 ; Giel & Nienhuis, 2001). All raters had
completed training in one of these instruments.
Age at onset of psychosis
Age at onset of ﬁrst psychosis was deﬁned by the age
of the patient at the time of onset of the ﬁrst psychotic
episode. To determine the age at ﬁrst psychosis : (1) we
used the CASH and the SCAN to assess psychotic
symptoms retrospectively ; (2) we determined whether
psychotic symptoms met the criteria for a ‘psychotic
episode’, deﬁned by the occurrence of at least one
of the following psychotic symptoms during at least
1 week: (a) hallucinations, (b) delusions and/or
(c) formal thought disorders ; and (3) we determined
when the onset of these symptoms occurred by asking
the patient and by using information from medical
ﬁles and collateral information from parents and/or
psychiatric caregivers.
Substance use
Substance use was assessed with a short version of the
Composite International Diagnostic Interview (CIDI ;
WHO, 1994), sections B (tobacco use), J (alcohol use)
and L (drug use). This version comprises items on the
quantity of tobacco use and alcohol use in the past
year, and items on the quantity and severity of illicit
drug use over the past year and lifetime. According to
the CIDI, patients were considered drug users if they
had used a particular drug ﬁve or more times.
Nicotine use was deﬁned as daily use of cigarettes
for at least 1 month in the past 12 months. Alcohol use
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in the past year was deﬁned as having consumedmore
than 12 alcoholic drinks in the past 12 months. Heavy
alcohol use in the past year was deﬁned as having
consumed more than 21 alcoholic units per week. Age
at onset of cannabis use was not assessed but we did
assess age at most intense cannabis use, deﬁned as the
age at which the cannabis was used most frequently.
To determine whether most intense cannabis use had
occurred prior to psychosis onset, we subtracted age at
most intensive cannabis use from age at onset of ﬁrst
psychosis.
In addition to the structured interviews, we used
urinalysis to detect current cannabis use [the presence
of the tetrahydrocannabinol (THC) metabolite 11-nor-
delta-9-THC-9-carboxylic acid was assessed with
immunoassays with a cut-oﬀ of 50 ng/ml], current
amphetamine use (the presence of D-methampheta-
mine was assessed with immunoassays using a cut-oﬀ
of 1000 ng/ml) and current cocaine use (the presence
of benzoylecgonine was assessed with immunoassays
using a cut-oﬀ of 300 ng/ml).
We deﬁned three subgroups based on drug use
history :
(a) a subgroup of patients who never used drugs (NO
DRUGUSE), that is patients who (1) reported no illicit
drug use in the past year or lifetime in the CIDI,
and (2) had negative urine screens for THC,
cocaine and amphetamines.
(b) a subgroup of patients who had used cannabis
but no other illicit drugs (ONLY CAN), that is patients
who (1) reported cannabis use in the past year
and/or lifetime but no other drug use in the CIDI,
and (2) had negative urine screens for ampheta-
mines and cocaine.
(c) a subgroup of patients who had used cannabis and
other illicit drugs that can precipitate psychosis
(CAN+OTHER DRUGS), that is patients who reported
cannabis use and other drug use (cocaine, ecstasy,
hallucinogens and/or stimulants) in the past year
and/or lifetime in the CIDI.
Statistical analysis
x2 tests were used to determine group diﬀerences
for categorical variables. One-way between-groups
analyses of variance (ANOVAs) and t tests were con-
ducted to explore group diﬀerences for continuous
variables.
A linear regression model was ﬁtted with age at
onset of ﬁrst psychosis as the dependent variable, and
patient subgroup (NO DRUG USE, ONLY CAN, CAN+OTHER
DRUGS), gender and patient subgroup by gender inter-
action as independent variables. Nicotine use and
alcohol use in the past year were entered as covariates.
We used Kaplan–Meier analyses to assess the eﬀect
of drug use history (NO DRUG USE, ONLY CAN, CAN+OTHER
DRUGS) on age at onset of ﬁrst psychosis. The log-rank
test was used to compare the survival distributions
between the diﬀerent subgroups. As the survival
curves of the diﬀerent subgroups crossed, we de-
cided not to perform Cox regression analysis (because
the proportional hazards assumption implies non-
crossing survival curves). Separate Kaplan–Meier
analyses were performed for males and females.
Results
Sample characteristics
In 785 patients [599 males (76.3%) and 186 females
(23.7%)], inclusion criteria for one of the subgroups
according to drug use history (NO DRUG USE, ONLY
CAN, and CAN+OTHER DRUGS) were met. The numbers of
patients per subgroup were: NO DRUG USE 281 (35.8%),
ONLY CAN 223 (28.4%), CAN+OTHER DRUGS 281 (35.8%). In
the can+other drug group (n=281), lifetime preva-
lence was 51.6% for stimulant use, 52.7% for
cocaine use, 48.8% for hallucinogen use, and 66.9%
for ecstasy use.
DSM-IV diagnoses of the patients were : schizo-
phrenia (n=528, 67.3%), schizo-aﬀective disorder
(n=93, 11.8%), schizophreniform disorder (n=44,
5.6%), psychotic disorder NOS (n=79, 10.1%), and
other psychotic disorders (n=41, 5.2%). Sample
characteristics stratiﬁed by drug use history and gen-
der are shown in Table 1. For 457 patients (398 males
and 59 females), the age at most intensive cannabis use
was available (mean=19.5, S.D.=4.4 years ; Table 1).
Age at most intensive cannabis use did not diﬀer
statistically (p=0.148) between males (mean=19.4,
S.D.=4.1 years) and females (mean=20.5, S.D.=5.6
years). In 63.5% of the patients, age at most intensive
cannabis use preceded the age at onset of ﬁrst psy-
chosis, with a mean of 4.4 years (S.D.=3.8). There were
no statistically signiﬁcant diﬀerences between males
and females in this percentage (64.3% v. 57.6%,
x2=1.0, p=0.319).
Comparison of age at onset of ﬁrst psychosis
between subgroups according to drug use history
Fig. 1 shows the mean age at onset of ﬁrst psychosis
with 95% conﬁdence intervals (CIs), stratiﬁed for
subgroups according to drug use history and gender.
As no statistically signiﬁcant gender by drug use his-
tory interaction was found in the prediction of age at
onset of ﬁrst psychosis, only main eﬀects without the
gender by drug use history interaction are presented
(Table 2).
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Table 1. Sample characteristics of total study sample (n=785), stratiﬁed by (a) drug use history and (b) gender
(a)
Total
(n=785)
No drug use
(n=281)
Only cannabis
(n=223)
Cannabis
and other
drugs
(n=281) x2 or F df p value
Male gender, n (%) 599 (76.3) 159 (56.6) 180 (80.7) 260 (92.5) 103.7 2 <0.001
Age (years), mean (S.D.) 27.2 (7.2) 28.8 (8.5) 26.8 (6.9) 26.1 (5.7) 10.9 2, 782 <0.001a
Illness duration (years), mean (S.D.) 4.1 (3.7) 4.2 (3.8) 4.3 (4.2) 3.9 (3.3) 1.1 2, 782 0.343
Ethnicity : Caucasian, n (%) 616 (78.5) 233 (82.9) 161 (72.2) 222 (79) 8.5 2 0.014
Nicotine use past year, n (%) 508 (65.0) 85 (30.6) 178 (79.8) 245 (87.5) 228.8 2 <0.001
Alcohol use past year, n (%) 579 (74.2) 166 (59.7) 172 (77.8) 241 (85.8) 51.7 2 <0.001
Alcoholic heavy use past year, n (%) 55 (7.0) 5 (1.8) 20 (9.0) 30 (10.7) 18.9 2 <0.001
Age most intensive cannabis use (years), mean (S.D.) 19.5 (4.4) – 19.7 (4.8) 19.4 (4.0) 2.9 455 0.456
(b)
Total
(n=785)
Males
(n=599)
Females
(n=186) x2 or t df p value
Male gender, n (%) 599 (76.3)
Age (years), mean (S.D.) 27.2 (7.2) 26.7 (6.6) 29.0 (8.9) 3.3 250.6b 0.001
Illness duration (years), mean (S.D.) 4.1 (3.7) 4.1 (3.7) 4.4 (4.0) 0.7 783 0.460
Ethnicity : Caucasian, n (%) 616 (78.5) 464 (77.5) 152 (81.7) 1.5 1 0.217
Nicotine use past year, n (%) 508 (65.0) 421 (70.6) 87 (47) 34.6 1 <0.001
Alcohol use past year, n (%) 579 (74.2) 462 (77.5) 117 (63.6) 14.3 1 <0.001
Alcoholic heavy use past year, n (%) 55 (7.0) 50 (8.3) 5 (2.7) 7.0 1 0.008
Age most intensive cannabis use (years), mean (S.D.) 19.5 (4.4) 19.4 (4.1) 20.5 (5.6) 1.5 67.6b 0.148
S.D., Standard deviation ; df, degrees of freedom.
a Post-hoc Bonferroni test : NO DRUG USE>ONLY CAN, NO DRUG USE>CAN+OTHER DRUGS.
b Equal variances not assumed.
Figures in bold have adjusted standardized residuals>3.0 ; ﬁgures in italics have adjusted standardized residuals<x3.0.
Percentages in the columns and means are sometimes based on less than n presented in the top row, because of missing data in the CIDI data.
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After controlling for gender, nicotine use and al-
cohol use in the past year, mean age at onset of psy-
chosis was signiﬁcantly diﬀerent between patients
from the NO DRUG USE, ONLY CAN and CAN+OTHER DRUGS
subgroups (F2,772=4.3, p=0.014). Mean age at onset of
ﬁrst psychosis in patients from the ONLY CAN group
was signiﬁcantly lower than mean age at onset of
psychosis in patients from the NO DRUG USE group
(adjusted diﬀerence of 1.7 years ; B=x1.7, S.E.=0.6,
t=x2.6, p=0.009). Furthermore, mean age at onset
of ﬁrst psychosis in patients from the CAN+OTHER DRUGS
group was also signiﬁcantly lower than the mean age
at onset of psychosis in patients from the NO DRUG USE
group (adjusted diﬀerence 1.8 years ; B=x1.8,
S.E.=0.6, t=x2.7, p=0.008). There was no signiﬁcant
diﬀerence in age at onset between the ONLY CAN and
CAN+OTHER DRUGS group.
Comparison of age at onset of ﬁrst psychosis
between males and females
Gender was signiﬁcantly related to age at onset of
psychosis, above and beyond illicit drug use, nicotine
use and alcohol use. Mean age at onset of psychosis
was signiﬁcantly lower in males than in females
(adjusted diﬀerence 1.3 years ; F1,772=5.6, p=0.018).
Fig. 2(a, b) shows Kaplan–Meier survival curves for
onset of ﬁrst psychosis stratiﬁed by drug use history
for male and female patients respectively. Log-rank
tests showed that, in both males and females, age at
onset of psychosis was signiﬁcantly diﬀerent between
the NO DRUG USE, ONLY CAN and CAN+OTHERS DRUGS sub-
groups (males : log rank x2=11.40, df 2, p=0.003,
females : x2=11.05, df 2, p=0.004). As shown in Fig 2,
diﬀerences in age at onset of ﬁrst psychosis be-
tween the NO DRUG USE group and the ONLY CAN and
CAN+OTHER DRUGS are most pronounced in the later-
onset group. This was conﬁrmed in a post-hoc re-
gression analysis performed on a younger subsample,
that is in a subgroup (n=426) of patients aged f26
years (we chose this cut-oﬀ because the median age
of the total group was 26 years). After controlling
for gender, nicotine use and alcohol use in the past
year, drug use status was not statistically signiﬁcant
in predicting age at onset (F2,416=2.8, p=0.06) in this
subgroup of patients.
Discussion
This large cohort study of patients treated for non-
aﬀective psychotic illness conﬁrms previous ﬁndings
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Fig. 1.Mean ages at onset of psychosis with 95% conﬁdence
intervals (CIs), stratiﬁed for subgroups according to drug use
history and gender. Males : mean age (95% CI) NO DRUG USE
23.2 (22.0–24.3), ONLY CAN 21.8 (21.0–22.5), CAN+OTHER DRUGS
21.7 (21.0–22.3) years. Females : mean age (95% CI) NO DRUG
USE 25.3 (23.7–26.8), ONLY CAN 22.6 (20.5–24.8), CAN+OTHER
DRUGS 21.1 (19.4–22.9) years.
Table 2. Summary of general linear regression analysis, with
total patient sample (n=785)a,b
B S.E. B t
Intercept 25.2
Drug use history, only
cannabis compared
to NO DRUG USE
x1.7 0.6 x2.6**
Drug use history, cannabis
and hard drugs
compared to NO DRUG USE
x1.8 0.7 x2.7**
Gender, male/female x1.3 0.6 x2.3*
Covariates
Nicotine use, yes/no x0.2 0.6 x0.4
Alcohol use, yes/no x0.4 0.5 x0.8
S.E., Standard error.
a General linear regression analysis, with age at onset of
psychosis as the dependent variable and drug use history
and gender as independent variables. The covariance
structure is unstructured. The B coeﬃcient indicates the
individual contribution of each predictor to the model. This
value indicates that, as the predictor increases by one unit,
age at onset of psychosis increases by the B value. A positive
B value means that, compared to the reference category, the
component score increases. A negative B value means that,
compared to the reference category, the component score
decreases. The t value indicates whether the predictor is
making a signiﬁcant contribution to the model. The larger
the value of t, the greater the likelihood that the predictor
makes a contribution to the model.
b Bold is used to indicate the reference category.
* p<0.05, ** p<0.01.
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that a history of cannabis use is associated with a
lower age at onset of ﬁrst psychosis, independent
of the eﬀects of gender or use of other drugs.
Furthermore, males had an earlier age at onset of
psychotic illness compared to females irrespective
of the use of cannabis, and the majority of both males
and females who had used cannabis had done so most
intensively prior to onset of psychotic illness.
Our ﬁnding that cannabis use was associated with
earlier age at onset of psychotic illness, independent
of the eﬀect of gender, is in line with the results of a
recent meta-analysis on this topic (Large et al. 2011).
We speculate that earlier onset of ﬁrst psychosis in
cannabis-using patients could be explained by (early)
cannabis use precipitating the onset of psychotic ill-
ness in vulnerable subjects. Support for this hypothesis
comes from studies in which age at onset of cannabis
use is positively associated with age at onset of high-
risk symptoms for psychosis (Dragt et al. 2010) and
with age at onset of psychotic illness (Barnett et al. 2007 ;
Estrada et al. 2011). Of note, the diﬀerence in age of
onset between the cannabis users and non-cannabis
users seems to bemost pronounced in the groupwith a
relatively late age of onset (Fig. 2a, b). The survival
curve from the study of Gonza´lez-Pinto et al. (2008),
with comparable subgroups of patients, shows a simi-
lar pattern. This may also explain why some studies in
schizophrenia patients did not ﬁnddiﬀerences in age at
onset between cannabis users and non-users : the age at
onset of psychosis in these studieswas around 20 years,
which is earlier than the age range where diﬀerences
occurred in our study (Bersani et al. 2002 ; DeRosse et al.
2010 ; Goldberger et al. 2010). It may also explain why
the absolute diﬀerences in age at onset between can-
nabis users and non-users diﬀers substantially across
studies. Studies with a later age at onset than in our
study may ﬁnd a larger diﬀerence in age at onset be-
tween users of cannabis and non-users. However, in a
recent meta-analysis on cannabis use and age at onset
of psychosis (Large et al. 2011), the ﬁnding of an as-
sociation between the proportion of cannabis users and
earlier age at onset was statistically independent of age
inclusion criteria.
Our ﬁnding that cannabis-related diﬀerences in
age at onset of psychosis are seen only in the group
with a relatively late age of onset might be explained
by recent ﬁndings from a genetic study (Pelayo-Tera´n
et al. 2010). In this study, age of onset of ﬁrst psychosis
in non-users of cannabis was signiﬁcantly later in
the catechol-O-methyltransferase (COMT) Met/Met
genotype carriers than in the COMT Val/Val and
COMT Val/ Met genotype carriers, whereas this as-
sociation was absent in users of cannabis. The authors
suggest that use of cannabis could exert a modulator
eﬀect on the genotype, suppressing the delay eﬀect
for the age of onset in the case of the Met allele
patients. Although this could be an explanation for our
ﬁndings, further studies are needed to conﬁrm our
preliminary ﬁndings and to clarify possible other
neurobiological mechanisms that make people vul-
nerable to the precipitating eﬀects of cannabis on
psychotic illness.
We did not ﬁnd a signiﬁcant diﬀerence in age at
onset between patients who had used only cannabis
and patients who had used both cannabis and other
illicit drugs. Our ﬁndings suggest that the additional
use of other drugs has no independent eﬀect on age at
onset of psychosis when adjusted for cannabis use.
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Fig. 2. Kaplan–Meier survival curves for age at ﬁrst psychosis
stratiﬁed by drug use history for (a) males (n=599) and (b)
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We found that male patients had a lower age of
onset of ﬁrst psychotic episode compared to female
patients, irrespective of the use of cannabis or other
illicit drugs. This is similar to the ﬁndings of Barnes
et al. (2006), but in contrast to those of other studies
(Veen et al. 2004 ; Gonza´lez-Pinto et al. 2008 ; Ongur
et al. 2009 ; Sugranyes et al. 2009 ; Barrigon et al. 2010 ;
De Hert et al. 2011), which may be explained by
the low power due to small groups of female patients
in most of these studies. However, lack of power
was not an issue in the one study that did include a
relatively large number (n=236) of females (De Hert
et al. 2011). It might be that using a diﬀerent proxy
for age at onset resulted in diﬀerent results regarding
gender diﬀerences in age at onset, because De Hert
et al. (2011) used age at onset of admission as a
proxy for age at onset and we used age at onset of
psychosis.
Later age at onset of psychosis in females has been
related to the modulating eﬀect of oestrogen, which is
thought to play a protective role in the disease process
of schizophrenia, resulting from a hypothesized anti-
dopaminergic eﬀect that could delay the development
of the disease (Szymanski et al. 1995). Another ex-
planation might be that psychosis is later recognized
by the environment in females compared to males,
resulting in treatment delays (Aleman et al. 2003).
Although we found signiﬁcant gender diﬀerences in
age at onset of psychosis irrespective of the use of
cannabis, we did not ﬁnd gender diﬀerences for the
mean age at most intensive use of cannabis (males 19.4
and females 20.5 years of age). Although other studies
on gender and age at most intensive cannabis use are
lacking, there are a few studies comparing age at onset
of ﬁrst cannabis use between males and females.
Those studies did not ﬁnd a diﬀerence between age at
ﬁrst use of cannabis between male and female patients
(mean 15.5 v. 15.4 years ; Dekker et al. 2008), or they
found a trend towards earlier ﬁrst use of cannabis
in males than in females (mean 15.6 v. 17.9 years ;
Barnett et al. 2007).
In the current study, 63.5% of cannabis users had
used cannabis most intensively prior to the onset of
ﬁrst psychosis, with no statistical diﬀerence in pro-
portion of males and females. As many patients from
both sexes use cannabis prior to ﬁrst psychosis and
cannabis aﬀects age at onset of ﬁrst psychosis in both
males and females, treatment interventions for canna-
bis use in prodromal and ultra-high-risk populations
should focus on both males and females.
Finally, as the largest proportion of patients used
cannabis most intensively before the onset of psy-
chosis, the self-medication hypothesis does not seem
to be supported in this study, at least not in the ma-
jority of patients. However, this ﬁnding does not fully
exclude the possibility of intensive cannabis use as an
attempt to reduce dysphoric or otherwise discomfort-
ing prodromal symptoms.
A limitation of the current study is that the age of
ﬁrst cannabis use was not assessed. A comparison be-
tween patients who started cannabis use prior to the
onset of psychosis and non-using patients might have
provided more robust conclusions about the possible
contribution of cannabis use to the onset of psychotic
illness. However, many of the cannabis-using patients
(64%) in the current study had used cannabis most
intensively prior to the onset of psychosis, which cor-
responds with previous ﬁrst-episode studies reporting
that 62–98% of cannabis-using patients had started
using cannabis before the onset of the ﬁrst psychosis
(Linszen et al. 1994 ; Buhler et al. 2002 ; Mauri et al.
2006 ; Barnett et al. 2007 ; Goldberger et al. 2010 ; Sevy
et al. 2010). Furthermore, studies in comparable patient
populations have reported a mean age at ﬁrst cannabis
use of 15.6 and 15.4 years (Dekker et al. 2008, 2010),
which is at least 5 years earlier than the mean age
at onset of psychosis in the current sample. Another
limitation of this study is that there could have been
recall bias on the dates of psychotic symptom onset
and dates of most intensive cannabis use. However, by
including only patients in whom psychiatric care for
psychosis had started less than 10 years ago (mean
illness duration was 4.1 years), recall bias was prob-
ably limited.
The strengths of our study are : (1) the large study
sample ; (2) we included patients presenting consecu-
tively either as out-patients or in-patients, reﬂecting
a sample of treated patients, which enhances the gen-
eralizability of our ﬁndings ; (3) a larger number of
females than in most of the previous studies, allowing
us to perform a suﬃciently powered regression
analysis in which the independent eﬀect of gender on
age at onset of psychosis was tested; and (4) we
checked urine for the presence of drugs in addition to
self-reported drug use.
In summary, this study shows that both cannabis
use and gender are independently associated with
an earlier age at onset of psychotic illness, above and
beyond the eﬀect of possible confounders, and that
the diﬀerence in age at onset between cannabis
users and never users seems to manifest itself in
the subgroup with a relatively late age of onset, that
is from the age of 23 years in males and 20 years in-
females. Our ﬁndings do not support the self-
medication theory, but point towards cannabis as a
precipitating factor in the development of psychosis.
Future studies are needed to clarify the neurobiologi-
cal factors that make people vulnerable for the pre-
cipitating eﬀects of cannabis use on age at onset of
psychotic illness.
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